Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Hana Vakil"'
Autor:
Scott A. Tomlins, Nickolay A. Khazanov, Benjamin J. Bulen, Daniel H. Hovelson, Melissa J. Shreve, Laura E. Lamb, Marc R. Matrana, Mark E. Burkard, Eddy Shih-Hsin Yang, William Jeffery Edenfield, E. Claire Dees, Adedayo A. Onitilo, Michael Thompson, Gary L. Buchschacher, Alan M. Miller, Alexander Menter, Benjamin Parsons, Timothy Wassenaar, Leon C. Hwang, J. Marie Suga, Robert Siegel, William Irvin, Suresh Nair, Jennifer N. Slim, Jamal Misleh, Jamil Khatri, Gregory Masters, Sachdev Thomas, Malek Safa, Daniel M. Anderson, Kat Kwiatkowski, Khalis Mitchell, Tina Hu-Seliger, Stephanie Drewery, Andrew Fischer, Komal Plouffe, Eric Czuprenski, Jennifer Hipp, Travis Reeder, Hana Vakil, D. Bryan Johnson, Daniel R. Rhodes
Publikováno v:
Communications Medicine, Vol 3, Iss 1, Pp 1-14 (2023)
Tomlins et al. develop an Immunotherapy Response Score (IRS) to predict clinical benefit from checkpoint inhibition across solid tumors. IRS integrates TMB and gene expression, is evaluable from FFPE material, and is predictive for real-world progres
Externí odkaz:
https://doaj.org/article/4592ab4c5780454fabd8956daa3f8f79
Autor:
Nickolay Khazanov, Melissa Shreve, Laura Lamb, Daniel Hovelson, Marc Matrana, Mark Burkard, Eddy Yang, William Edenfield, Claire Dees, Adedayo Onitilo, Michael Thompson, Gary Buchschacher, Alan Miller, Alexander Menter, Benjamin Parsons, Timothy Wassenaar, Leon Hwang, J. Suga, Robert Siegel, William Irvin, Suresh Nair, Jennifer Slim, Kat Kwiatkowski, Khalis Mitchell, Tina Hu-Seliger, Stephanie Drewery, Andrew Fischer, Jennifer Hipp, Travis Reeder, Hana Vakil, Bryan Johnson, Daniel Rhodes, Scott Tomlins
Pembrolizumab is approved in many advanced solid tumor types, however predictive biomarkers and the proportion of pembrolizumab-benefiting patients vary. Biomarkers beyond PD-L1 immunohistochemistry, microsatellite instability (MSI) status, and tumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5d44f832c2a2425bf32a36e8fa251391
https://doi.org/10.21203/rs.3.rs-1225960/v1
https://doi.org/10.21203/rs.3.rs-1225960/v1
Autor:
Daniel R. Rhodes, D. Bryan Johnson, Travis Reeder, Kat Kwiatkowski, Daniel H. Hovelson, Jennifer Hipp, Jayson Falkner, Hana Vakil, Lorena Lazo de la Vega, Stephanie Drewery, Khalis Mitchell, Javed Siddiqui, Paul W. Harms, Andrew H. Fischer, Scott A. Tomlins
Publikováno v:
The Journal of molecular diagnostics : JMD. 23(11)
Despite widespread use in targeted tumor testing, multiplex PCR/semiconductor (Ion Torrent) sequencing-based assessment of all comprehensive genomic profiling (CGP) variant classes has been limited. Herein, we describe the development and validation
Autor:
Eddy S. Yang, Malek M. Safa, Daniel R. Rhodes, Hana Vakil, Kat Kwiatkowski, Travis Reeder, Daniel H. Hovelson, Scott A. Tomlins, William Jeffery Edenfield, Mark E. Burkard, Bryan Johnson, Khalis Mitchell
Publikováno v:
Journal of Clinical Oncology. 39:2609-2609
2609 Background: P is approved in many ST types, however predictive biomarkers and the proportion of pts who benefit vary widely. Biomarkers beyond PD-L1 immunohistochemistry and comprehensive genomic profiling (CGP) based tumor mutation burden (TMB)
Autor:
Kat Kwiatkowski, Marc R. Matrana, Elizabeth Claire Dees, Jamil Khatri, Daniel M. Anderson, Daniel R. Rhodes, Jennifer Nadine Slim, Jennifer Marie Suga, Jayson Falkner, Eddy S. Yang, Hana Vakil, Alex R. Menter, Mark E. Burkard, Bryan Johnson, Malek M. Safa, Daniel H. Hovelson, Travis Reeder, Scott A. Tomlins, Han A. Koh, Benjamin M. Parsons
Publikováno v:
Journal of Clinical Oncology. 38:3574-3574
3574 Background: Tissue-based h-CGP is increasingly utilized for treatment selection in patients with advanced solid tumors but has high tumor surface area [TSA] requirements (≥25mm2 for leading commercial tests). P-CGP is recommended when tissue i
Autor:
Frank S Ong, Jerome I. Rotter, Kenneth E. Bernstein, Kandarp H. Shah, Rand B. Lee, Joshua L. Deignan, Wayne W. Grody, Terri Getzug, Hana Vakil, Kingshuk Das, Jane Z. Kuo, Yuan Xue, David L. Rimoin
Publikováno v:
Clinical Genetics. 84:55-59
Familial Mediterranean fever (FMF), inherited in an autosomal recessive manner, is a systemic auto-inflammatory disorder characterized by recurrent attacks of fever with peritonitis, pleuritis, synovitis and erysipeloid rash. The marenostrin-encoding
Autor:
Frank S Ong, Jane Z. Kuo, Wendell-Lamar B. Blackwell, Kenneth E. Bernstein, Wayne W. Grody, Mark O. Goodarzi, Hana Vakil, Jerome I. Rotter, Kingshuk Das, Jay Wang, Stephen Lim
In the field of oncology, clinical molecular diagnostics and biomarker discoveries are constantly advancing as the intricate molecular mechanisms that transform a normal cell into an aberrant state in concert with the dysregulation of alternative com
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::683395b498e4a997e84a83cbbf775852
https://europepmc.org/articles/PMC3495985/
https://europepmc.org/articles/PMC3495985/
Publikováno v:
Endocrine Connections, Vol 9, Iss 12, Pp 1135-1147 (2020)
Human (h) growth hormone (GH) production studies are largely li mited to effects on secretion. How pituitary hGH gene (hGH-N/GH1) expression is regulated is important in our understanding of the role hGH plays in physiology and disease. Here we asses
Externí odkaz:
https://doaj.org/article/114387348a3f4544b0a6ec6b8bfafe11
Autor:
Hana Vakili, Sharon Koorse Germans, Xiuhua Dong, Ankit Kansagra, Hetalkumari Patel, Alagarraju Muthukumar, Ibrahim A. Hashim
Publikováno v:
Diagnostics, Vol 10, Iss 4, p 219 (2020)
Background: Therapeutic humanized IgG1 kappa monoclonal antibody (t-mAb), daratumumab (DARA) is a Food and Drug Administration approved drug for the treatment of relapsed/refractory plasma cell myeloma (PCM). DARA appears on serum protein electrophor
Externí odkaz:
https://doaj.org/article/be98d13f8da44ee1a18d9676ddbd001c